Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.
Promotional spending is down as companies rationalize and optimize budgets. But in contrast to big changes on the sales side, marketers are still trying to make the old model work
To increase impact and effectiveness, personalized Web sites should be constructed in different ways to interact with multiple audiences.
Pharma can stand to win hearts, minds, and tax credits by launching an eco bandwagon
Only time will reveal CER's true definition, and determine the full effects of a CER-based system
Everyone has bad days, but do you know how to make the best of them?
The economy is turning around; leaders need to position their companies now for the market bounce.
NHS England is currently undergoing profound changes to introduce a new culture where clinicians and patients are the new stars, where competition is mandatory, where everything rests on patient outcomes and where collaboration and innovation are being encouraged at the highest levels of command.
I’ve been lucky enough to get a sneak preview of Across Health’s 2014 Multichannel Barometer report.
How to stretch that portfolio to make ends meet
The debate over gene sequence patents is leaving investors lost and confused. These strategies will help them find their way
The industry is a-changing. Here are eight seminal events that describe how.
Pharma’s image is still suffering despite a rise in medical innovation. Dan Bobear offers five patient-centered strategies that could help in finally mending the gap.
Veteran salesperson Reggie Smith of Genentech makes the case for sales force diversity
For years, medical education activities have been a sure way for pharma marketers to deliver key messages to the medical community about scientific discoveries, new treatments, and products fostering medical advancement. The most effective activities advance physicians' knowledge and motivate them to act.
The competition for generics' 180-day marketing exclusivity is fierce, and Dr. Reddy's Laboratories filed the first court case calling into question FDA's methods for determining exclusivity on a patent-by-patent basis.
As pharmaceutical companies look to emerging markets to offset slowed growth at home, success will depend on efficient re-use of regulatory content to target new high-growth markets.
With new access levers emerging, positioning products will require a shift form the traditional launch playbook.
Just a few years ago, financiers were celebrating the "recession-proof" US economy, betting on the success of dot-coms and ridiculing the cautious few. Today, pharma industry experts tout mergers and acquisitions as a panacea to solve growth problems, reduce costs, increase sales, and renew R&D productivity.